respiratory
AstraZeneca signs respiratory pact with Amgen
April 5, 2012Research and Development Amgen, AstraZeneca, MedImmune, respiratory
AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …
Health secretary calls for global action on lifestyle conditions
September 21, 2011cardiovascular, diabetes, respiratory, smoking
Health secretary Andrew Lansley has urged governments across the world to be “bold and determined” in working together to tackle …
Novartis to close UK manufacturing site, research downsized
March 16, 2011Research and Development Horsham, Novartis, respiratory
Novartis is to close its manufacturing site in Horsham, West Sussex, but will retain its work in respiratory research at …
AZ accepts $92.5m to settle respiratory dispute
February 18, 2011Sales and Marketing AZ, AstraZeneca, MedImmune, PDL BioPharma, Synagis, patent dispute, respiratory
AstraZeneca’s MedImmune subsidiary is to receive $92.5 million as part of a legal settlement involving its respiratory drug Synagis. PDL …
AstraZeneca takes $445m hit to halt motavizumab
December 22, 2010Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus
AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …
GSK’s Relovair moves into phase III
March 19, 2010Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory
GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …
GSK acquires respiratory candidate
February 4, 2010Research and Development Apeiron, GlaxoSmithKline, respiratory
GlaxoSmithKline has acquired exclusive rights to a biotherapeutic enzyme developed for use against Acute Respiratory Distress Syndrome (ARDS). The move …
GSK begins phase III COPD trials
October 28, 2009Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory
GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
